NASDAQ · SLN
Silence Therapeutics plc
$19.80+$0.09 (+0.46%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
Loading market information…
NASDAQ · KYTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Kyverna Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kyverna Therapeutics, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.68. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kyverna Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:40 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 27, 2025 |
| -$0.88-1.15% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$0.80-3.9% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $25.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$19.80+$0.09 (+0.46%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
$1.25-$0.05 (-3.85%)
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.97% below the high.
$6.63+$0.40 (+6.42%)
Capricor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.58% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
$9.33+$0.18 (+1.97%)
Contineum Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.55% below the high.
$11.31+$0.38 (+3.43%)
Lyell Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.88% below the high.
$1.59+$0.07 (+4.28%)
Cabaletta Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.53% below the high.
